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Available online 10 March 2016Objective:The aimof this studywas to verify thehypothesis originated frombioinformatics and literature reviews
that hnNRP A1 may be a new immune target of Behçet's disease (BD).
Methods: First, bioinformatics was used to show the correlation between hnRNP A1 and A2/B1 in amino acid
sequences and three dimensional structures. Second, hnRNP A1 was expressed, puriﬁed, and immunologically
conﬁrmed by systematic immunology methods including: Western blotting, immunoprecipitation and Dot-
ELISA. Then, ELISA was used to screen the anti-hnRNP A1 autoantibodies in newly conﬁrmed clinical samples
and the clinical signiﬁcancewas compared between anti-hnRNP A1 antibody positive and negative groups. Final-
ly, the endothelial cells antigen proﬁle of one anti-hnRNP A1 antibody positive BD patient was detected using im-
munoprecipitation with liquid chromatography tandemmass spectrometry (LC–TMS).
Results: In total 720 subjects enrolled and tested in this study. Our results demonstrated hnRNP A1 as a new im-
mune target of BD. The reactivity of BD serum IgG antibodies against hnRNP A1 was signiﬁcantly higher than
healthy controls (P b 0.0001), and deep vein thrombosis (DVT) showed a signiﬁcant higher in the anti-hnRNP
A1 antibodies positive group (P b 0.05).
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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HnRNP A11. Introduction
Behçet's disease (BD) is a chronic systemic autoimmunediseasemain-
ly characterized by recurrent oral ulceration, genital ulceration anduveitis
(Pineton de Chambrun et al., 2012; Mendes et al., 2009), which can also
affect all kinds of blood vessels, joints, nervous and gastrointestinal sys-
tems (Mendes et al., 2009). Vasculitisis considered playing a key role in
BD pathogenesis, resulting from most of the symptoms observed during
the process of this disease. However, the pathogenesis of BD is not clear,
and the diagnosis is based on a typical clinical syndrome, no serum test
speciﬁc for BD is yet available (Mor et al., 2002).hrombosis; SLE, systemic lupus
C–TMS, liquid chromatography
e membranes; PBS, Phosphate
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. This is an open access article underLike other classical autoimmune diseases, such as systemic lupus ery-
thematosus (SLE) and rheumatoid arthritis (RA), BD also exhibits a great
diversity of clinical manifestations, indicating the co-existence of a large
number of autoantigens (Hsieh and Yu, 2013; Sherer et al., 2004; Nell
et al., 2005). Endothelial function has a close relationshipwith BD pathol-
ogy (Balta et al., 2014a, 2014b, 2014c). Anti-endothelial cell antibodies
(AECA), which are related to autoimmune vascular injury, have been
found involved in many rheumatism diseases (Yoshio, 1993; Yoshio
et al., 1994). They have also been detected in BD patients and proven to
be associated with vasculitis symptoms (Dinc et al., 2003; Aydıntug
et al., 1993). Researchers have emphasized the key role of AECA in BD
in thepast decades, for example, hnRNPA2/B1was successively identiﬁed
in human dermal microvascular endothelial cells as an AECA autoantigen
of BD (Cho et al., 2012; Liang et al., 2015). And subsequent experiments
proved that this valuable antigen play an important role in this disease's
pathological process (Cho et al., 2013). Recently, at least four new targets
of AECA inBD, like prohibitin,HSP27, ETFB andannexinA2have been suc-
cessfully identiﬁed by our group (Xun et al., 2014; Chen et al., 2015a,
2015b, 2015c). Theseﬁndings, not only addednew information to explain
the AECA related pathology, but also further conﬁrmed the key role of
AECA in the process of BD. In patients with BD, vascular involvementthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
The characteristics of samples used in this study.
Group (number) Average age (Range) Gender (Female)
Behçet's disease (186) 37(14–80) 78
Systemic lupus erythematosus (184) 37(15–75) 152
Rheumatoid arthritis (176) 34(14–68) 135
Healthy controls(174) 28(25–35) 114
216 P. Chen et al. / EBioMedicine 6 (2016) 215–221and thrombotic tendency is a potentially life risk condition (Balta et al.,
2014a, 2014b, 2014c). Deep vein thrombosis (DVT) is the most common
manifestation but other organs may also be involved (Balta et al., 2015a,
2015b). Thrombotic events may be associated so many conditions and
its treatment may cause serious complications (Balta et al., 2015a,
2015b). More useful details should be explored to differential diagnosis
BD patients with DVT and guide its treatment.
Bioinformatics as a useful protein analysis tool has beenwidely used
in the research of autoimmune diseases. The possible role of HSPs
proteinswere analyzed by bioinformatics approach, suggesting thatmi-
crobial HSPs, which cross-react with host related proteins and trigger
immune responses are possible pathogenic factors involved in the
development of BD (Ghasemi et al., 2012). HLA B*5101, which is gener-
ally accepted as a geneticmarker of BD, can be highly recognized by sev-
eral short sequences through computerized programs (Baharav and
Weinberger, 2012).
HnRNP A1 and A2/B1 were also coexisted in many rheumatic
diseases as hnRNP A/B complex antigens. For examples, autoanti-
bodies for A and B proteins of the hnRNP complex have been detect-
ed in RA in late 1980s (Caporali et al., 2005). Among 10 hnRNPs, the
highest identity was observed between hnRNP A1 and A2/B1 in
many systemic rheumatic diseases (Op De Beéck et al., 2012).
Using bioinformatics tools, we found that hnRNP A1 and A2/B1
have high protein sequence and structure homology, and many anti-
gen epitopes were shared between them. Theoretical and experi-
mental phenomenon enlightens us that hnRNP A1 may be an
autoantigen of BD, too. Above all, traditional immunology Western
blotting was used to address this hypothesis, the immunoprecipita-
tion and Dot-ELISA further conﬁrmed the preliminary result.
2. Subjects and Methods
2.1. Subjects
In this study, serological criteria were evaluated through the assess-
ment of 720 subjects in total, the data about epidemiology were shown
in Table 1. Including1) BDpatients: 186BDpatientswere used for doing
large set test. 2) Disease control: 184 SLE patients; 176 RA patients.Fig. 1. Sequence alignment of hnRNP A1 and A2/B, and the similarly amino aci3) Healthy control: Blood samples of 174 healthy people were provided
by our clinical part. The diagnosis for BD is fulﬁlled by the criteria pro-
posed by the International Study Group (International Study Group for
Behçet's Disease, 1990). The BD patients were collected from the Chi-
nese PLA General Hospital and Shanxi DaYi Hospital, and the disease
and healthy controls were collected from the Chinese PLA General Hos-
pital. This study was approved by the ethical committee of the Chinese
PLA General Hospital and Shanxi DaYi Hospital, and each patient in-
volved gave informed consent. Samples were collected, dispensed and
stored at−80 °C before further tests.
2.2. Antigenic Determinant Prediction
As aforementioned, since hnRNP A2/B1 was a probable antigen of
BD, hnRNP A1 and A2/B1were selected to perform sequence alignment.
Sequence alignment was performed with default parameters using
Gonnet 250 protein weight matrix by Clustalx software (EMBL, Heidel-
berg, Germany) (Altschul et al., 1990). Then Bepipred Linear Epitope
Prediction (Larsen et al., 2006) was used to predict epitopes of two
proteins. Potential common epitopes of two proteins were selected
with standards that amino acid lengths were no less than 8 and co-
occurred in both hnRNP A1 and A2/B1. The protein structure was ob-
tained from published literatures. Similarity analysis of protein struc-
tures was used ﬂexible structure alignment by chaining aligned
fragment pairs allowing twists (FACAT) method (Ye and Godzik, 2003
,2004), which is a method for ﬂexible protein structure comparison. It
simultaneously addresses the two major goals of ﬂexible structure
alignment, optimizing the alignment and minimizing the number of
rigid-body movements in the reference structure.
2.3. Protein Cloning, Expression and Puriﬁcation
Total RNA was isolated from EA.hy926 cell using TRIzol reagent
(Invitrogen, CA). RT-PCR was carried out according to the
manufacturer's instruction (Fermentas, MD). Human hnRNP A1 pro-
tein was overexpressed in Escherichia coli BL21, followed by the pu-
riﬁcation of recombinant proteins using Ni-NTA resin (CWBIO,
Beijing, China). The concentration of protein was determined by
BCA assay kit (Biosynthesis Biotechnology, Beijing, China). Puriﬁed
recombinant protein was conﬁrmed by mass spectrometry (Applied
Biosystems, Foster City, CA).
2.4. Western Blotting
Human umbilical vein cell line (EA.hy926)was used in this study. The
EA.hy926 was cultured in DMEM (HyClone, UT) containing 10% fetal bo-
vine serum (HyClone, UT). Cell lysateswere loaded into thewells of a 12%ds was traced black. High similarity between their sequences was shown.
Fig. 2. Antigenic epitopes prediction and structure comparison between hnRNP A1 and A2/B1. (A) Antigenic epitopes distribution of hnRNP A1 and A2/B1. Epitope sequences were
displayed beyond the underlines. Antigenic epitopes prediction result of hnRNP A1 and hnRNP A2/B1 where the thresholds of predicted residue scores are 0.898 and 0.871
respectively. The yellow indicates feasible epitopes but the green not. (B) Similar part of protein structure was shown.
217P. Chen et al. / EBioMedicine 6 (2016) 215–221polyacrylamide gel and separated. The gel was then transferred onto
polyvinylidene ﬂuoride membranes (PVDF; Merck Millipore, MA) that
had been washed twice with ultrapure water. The PVDF membranes
were then blockedwith 5% nonfat milk in PBS at 4 °C for 1 h and then in-
cubatedwith 10 BD sera thatwere randomly selected (1:500dilutions) or
sera from random healthy controls at 4 °C for 12 h. Themembranes were
extensively washed 4 times with 0.5% PBST buffer to remove unbound
antibodies. Last, they were incubated with horseradish-peroxidase-
conjugated goat anti-human IgG (ImmunoHunt, Beijing, China) for 1 hFig. 3. Gene ampliﬁcation, expression, puriﬁcation of hnRNP A1. (A) The right band is
marker.(B) Constructed vectors of PET-28 and hnRNP A1were identiﬁed by double restriction e
(C) The IPTG inducible expression of E. coli BL21. Lane 1–8: the corresponding IPTG concent
(E) Veriﬁcation of hnRNP A1 by mass spectrometry. The target protein is identiﬁed as hnRNP Aat 37 °C, and ECL detection was carried out in accordance with the prod-
uct instructions (Applygen, Beijing, China).
2.5. ELISA
The capture recombinant proteins (300 ng/mL) were used to coat
the 96 well microplate (Corning, NY) overnight at 4 °C. After three
washes with PBST, each well was blocked in 200 μL 5% goat serum for
2 h at 37 °C. Then the plate was incubated with 100 μL sera dilutedthe hnRNP A1 gene production after PCR ampliﬁcation, left band is DNA weight
nzyme digestion. 1: DNAmarker; 2: The bands after double restriction enzyme digestion.
ration is 0, 0.1, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5 mM in turn. (D) Puriﬁed hnRNP A1 protein.
1.
Fig. 4. Antigenicity of hnRNP A1 in BD patients. (A) The western blotting validation result
of hnRNP A1 probedwith 10 BDpatient sera at dilutions of 1:500 and HC controls. (B) The
hnRNP A1 protein band was clearly present in the immunoprecipitates (band 2, 4, 6), but
not in supernatant (band 1, 3, 5). (C) Veriﬁcation of immunoprecipitates band by mass
spectrometry. The mascot score was 244 for hnRNP A1, further indicating that the
hnRNP A1 protein was a potential target antigen of BD. (D) Dot-ELISA result. Three
positive results were then used to perform Dot-ELISA to assure the antigenicity of
hnRNP A1. Compared with healthy control (HC1), only BD sera show positive result. BD:
Behçet's disease, HC: healthy controls.
218 P. Chen et al. / EBioMedicine 6 (2016) 215–2211:100 in PBS for 2 h at 37 °C. Threewashes later, 100 μL goat anti-human
IgG/HRP (ImmunoHunt, Beijing, China) was added to each well and the
plate was then incubated for an additional 1 h at 37 °C. The absorbance
of each well was measured with a plate reader at 450/620 nm (Tecan,
Hombrechtikon, Switzerland).
2.6. Statistical Analysis
The clinical characteristics were analyzed by chi-square test and
ELISA data was implemented t test with SPSS software (Version 17,
Chicago, IL). P values less than 0.05were considered signiﬁcant. The crit-
ical point for positive deﬁnition was a number with a higher value than
that of the healthy controls (Mean + 3 SD).
In-gel digestion and mass spectrometry analysis, dot-ELISA, immu-
noprecipitation, and indirect immunoﬂuorescence assays were shown
in supplementary materials.
3. Results
3.1. Bioinformatics Analysis
Sequence alignment of hnRNP A1 and A2/B was performed as
described in method chapter. The homology of two proteins was 62%
(Fig. 1.). The high sequence similarity indicates that they have similarity
immunogenicity. In the result of Bepipred Linear Epitope Prediction,
epitopes were predicted for hnRNP A1 and A2/B1 respectively
(Fig. 2A.). The part three-dimensional structure proteins (hnRNP A1:
1-184aa; hnRNP A2/B1:1-103aa) were obtained from Protein Data
Bank database (http://www.rcsb.org). Structure pairs with probability
b0.05 are signiﬁcantly similar. After alignment, the two structures are
signiﬁcantly similar with P value of 2.45e−09 (raw score is 234.45)
(Fig. 2B). This indicates hnRNP A1 and A2/B1 have strong similarity in
the molecular level and reveals the similarity immunity quality.
3.2. The Expression and Puriﬁcation of hnRNP A1
HumanhnRNPA1 genewas ampliﬁed by Polymerase Chain Reaction
(PCR) technique. The production was veriﬁed by 1% Agarose Gel Elec-
trophoresis. A target bandwas obtained at 900 bp and no other speciﬁc
ampliﬁcation appeared (Fig. 3A.). The expression vector was validated
by double enzymes restriction (Fig. 3B.).
Protein expression and puriﬁcation technology was used here ac-
cording to our routine optimized method to obtain the recombinant
human hnRNP A1 protein (Fig. 3C and D.). The protein obtained by Ni-
NTA resin was reassured by mass spectrometry. The result shows that
individual ions scores are muchmore than 70, indicating that the puta-
tive protein is a highly homologous identity (Fig. 3E.).
3.3. Western Blotting
To further test the ability of the sera antibodies that could bind to
recombinant human hnRNP A1 protein, an SDS-PAGE analysis was per-
formed. Recombinant human hnRNP A1 protein could successfully be
recognized by three of ten BD sera by western blotting (Fig. 4A.).
These results proved that hnRNP A1 was an autoantigen of BD.
3.4. Immunoprecipitation
Immunoprecipitation was performed to verify the result of the
Western blotting. As shown in Fig. 4B, the band for the hnRNP A1 pro-
tein was clearly present in the immunoprecipitates, which was
conﬁrmed by mass spectrometry (Fig. 4C.), indicating that the hnRNP
A1was a real target antigen of BD. And, the dot-ELISA result of BD is con-
sistent with the immunoprecipitation too (Fig. 4D.).3.5. The Prevalence of the Anti-hnRNP A1 Autoantibody in BD Patients
ELISA was performed to determine the reactivity of serum IgG
antibodywith recombinant humanhnRNPA1. The critical point for pos-
itive deﬁnition was a number with a higher value than that of the
healthy controls (Mean + 3 SD). The hnRNP A1 antibody was
detected in 54 of 186 BD patients (29%), 40 of 184 SLE patients (22%),
71 of 176 RA patients (40%), and1 of 174healthy controls (b1%). The re-
activity of BD serum IgG against human recombinant hnRNPA1was sig-
niﬁcantly higher than healthy controls (P b 0.0001) (Fig. 5A.).We found
that the optical densities of anti-hnRNP A1 antibodies showed signiﬁ-
cant difference between DVT BD patients and normal BD patients with-
out DVT (P b 0.0001) (Fig. 5B.).
219P. Chen et al. / EBioMedicine 6 (2016) 215–2213.6. Clinical Signiﬁcance
The patients with detailed clinical information were analyzed. By
comparing the clinical information between the anti-hnRNP A1 anti-
body positive and negative groups, we found 9 BD patients with DVT
in 54 anti-hnRNP A1 antibody positive patients, while 8 patients with
deep vein thrombosis in 131 anti-hnRNP A1 antibody negative patients.DVT BD patients showed a signiﬁcant difference between anti-hnRNP
A1 antibody positive group and in the negative group (P b 0.05). Other
clinical symptoms (recurrent oral ulcers, recurrent genital ulcers, ante-
rior uveitis, skin lesions, gastrointestinal system involvement, nervous
system involvement and urinary system involvement) showed no sig-
niﬁcant differences between the anti-hnRNP A1 antibody-positive and
in the negative groups (Fig. 5C.).
3.7. HnRNP A1 and hnRNP A2/B1 Were Detected Co-existing in an Anti-
hnRNP A1 Antibody Positive BD Patient
Follow on ELISA test, immunoprecipitation with extracts of EA.hy
926 cells and BD sera was analyzed by liquid chromatography
tandem mass spectrometry. In the antigen and antibody complex,
two unique peptides of hnRNP A1 (SSGPYGGGGQYFAKPR and
NQGGYGGSSSSSSYGSGR) were identiﬁed. And, hnRNP A2/B1 was
also been found co-existed by hnRNP A1 (Fig. 6). This further validat-
ed our hypothesis from bioinformatics. Another important endothe-
lial cell antigen Annexin A2 was found again, indicating that this
method was reliable. In healthy control, any peptide of hnRNP A1
and A2/B1 was not found.
4. Discussion
HnRNP A1 has been reported as an important autoantigen of the
autoimmune response in rheumatic diseases inmany articles. Autoanti-
bodies to hnRNP complex have been detected in patients with RA, SLE
and mixed connective tissue disease in succession (so RA and SLE are
chosen in this study as disease control) (Hassfeld et al., 1989; Isenberg
et al., 1994). Recent researches indicated that hnRNP A1 can become
target for autoantibodies in other autoimmune diseases, such as
systemic sclerosis, Sjogren's syndrome, dermatomyositis (Generini
et al., 2009; Op De Beéck et al., 2012) which supposed that hnRNP A1
may contribute in the regulation of inﬂammation (Noguchi et al.,
2009). Compared with other classic disease speciﬁc autoantibodies
(such as anti-SSA and CCP), autoantibodies to the hnRNP-A1 display a
more common feature and exist in many rheumatic diseases (Steiner
et al., 1996). Thus we believed that hnRNP A1was not a candidate diag-
nostic marker in clinical application for all BD patients.
In this study, hnRNP A1 was ﬁrstly identiﬁed also as a target anti-
gen of BD. About 30% BD patients have circulating antibodies to
hnRNP A1 in Han Chinese (both the independent ELISA and WB
assay got the similar results). By comparing the clinical information
between the anti-hnRNP A1 antibody positive and negative groups,
DVT showed a signiﬁcant higher in the anti-hnRNP A1 antibodies
positive group (P b 0.05). Many proteins have been proved with
close relationship with BD process. Serum endocan levels as a mark-
er of disease activity in patients with BD has been found (Balta et al.,
2014a, 2014b, 2014c). However, the relationship between hnRNP A1
and DVT has not been reported.Fig. 5. Reactivity of sera IgG antibodies against hnRNP A1. (A) ELISA was performed to
detect the reactivity of serum IgG antibodies against human recombinant hnRNP A1
protein. The reactivity of BD serum IgG antibodies against human recombinant hnRNP
A1 was signiﬁcantly higher than healthy controls (P b 0.0001). (B) Anti-hnRNP A1
antibodies showed signiﬁcant difference between BD patients with DVT and normal BD
patients. The critical point for positive deﬁnition was a number with a higher value than
that of the healthy controls (Mean + 3 SD). Data in A are expressed as mean ± SD, the
plot whiskers of B mean min to max data and P value analyzed by the t test. (C) BD-
related manifestations in IgG anti-hnRNP A1 antibody positive and negative group
Comparing the clinical information between the anti-hnRNP A1 antibody-positive and
negative groups. The ratio was obtained from (Numberclinical+/Numberpositive)
(Numberclinical+/Numbernegative). The data were analyzed using SPSS software
(Version 17, Chicago, IL). BD: Behçet's disease, HC: healthy controls, RA: rheumatoid
arthritis, SLE: systemic lupus erythematosus. DVT: deep vein thrombosis, ROU: recurren
oral ulcers, RGU: recurrent genital ulcers, NI: nervous involvement, UI: urinary
involvement, SKIN: skin involvement, DVT: deep vein thrombosis, LI: lung involvement
GI: gastrointestinal involvement..
/
t
,
Fig. 6. HnRNP A1 and hnRNP A2/B1 antibodies were detected co-existed in one anti-hnRNP A1 antibody positive BD patients. (A) HnRNP A2/B1 was identiﬁed by mass spectrometry
(SwissProt Accession number, P22626). Matched unique peptides of hnRNP A2/B1 were shown. (B) The staining pattern of EA.hy926 cells by this anti-hnRNP A1 antibody positive
serum with indirect immunoﬂuorescence method. (C)Twelve unique peptides matched one endothelial cells antigen annexin A2 (SwissProt Accession number, P07355) of BD.
(D) Two matched peptides of hnRNP A1 (SwissProt Accession number, P09651) and their fragments were shown.
220 P. Chen et al. / EBioMedicine 6 (2016) 215–221Intriguingly, existing literatures have proved that hnRNP A1was related
to virus infection (Lin et al., 2009; Kim et al., 2007). Many researchers
believed that the onset of BD is associated with microbial infection.
Sometimes anti-HSV antibody can be detected in the circulation
serum of BD patients (Sohn et al., 2001), furthermore, the role of Strep-
tococcus sanguis in BD immunopathogenesis has been reported in sever-
al studies before (Mizushima, 1989; Isogai et al., 1990). HnRNP A1 may
be a considerable molecular in the process of BD pathology by mediat-
ing infection of pathogenic microorganisms, further inducing the endo-
thelial cells dysfunction, initiating inﬂammatory response and
triggering a stronger autoimmune response.
Bioinformatics was successfully used as a tool here to ﬁnd new
autoantigen of BD. With the application of a variety of high-
throughput technologies, we received more and more data in, and one
big data time about human autoimmune disease research is coming.
This study is the starting point of bioinformatics applications in ourteam, but not a destination. More bioinformatics analysis and experi-
ments will be performed to reveal the essential association between
hnRNP A1 and A2/B1 antigens.
Future work will focus on developing high speciﬁcity in vitro anti-
hnRNP A1 immunoassay as well as striving to extend the assay to
more autoimmune disease patients from multi-medical centers. And
the co-exist condition of hnRNP A1, hnRNPA2/B1 and relevant peptides
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